Mereo BioPharma Group (Mereo BioPharma Group) Change In Payables And Accrued Expense : $-1.97 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Change In Payables And Accrued Expense?

Mereo BioPharma Group's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $-0.91 Mil. It means Mereo BioPharma Group's Accounts Payable & Accrued Expense declined by $0.91 Mil from Jun. 2023 to Dec. 2023 .

Mereo BioPharma Group's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-1.97 Mil. It means Mereo BioPharma Group's Accounts Payable & Accrued Expense declined by $1.97 Mil from Dec. 2022 to Dec. 2023 .

Mereo BioPharma Group Change In Payables And Accrued Expense Historical Data

The historical data trend for Mereo BioPharma Group's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Change In Payables And Accrued Expense Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-8.82

-4.84

-1.70

1.46

-1.97

Mereo BioPharma Group Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial												-0.12	1.65	-0.19	-1.07	-0.91

Mereo BioPharma Group Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.97 Mil.

Mereo BioPharma Group Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.